Article · 29 Jun 2026
Conference abstractPublished 28 Sep 2015
4-1BB as an immune target
Stanford University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Preclinical update on anti-CD137 Mab and Trastuzumab stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy of Trastuzumab, Cetuximab, and Rituximab in HER2-expressing breast cancer, EGFR+ head and neck cancer, and CD20+ lymphoma. My focus is on NK cells and translational research work that led from an initial in vitro observation to Phase 1 clinical studies. The starting observation was that primary human NK cells in the presence of a CD20-positive cell line and rituximab for 24 h upregulated CD137 (4-1BB) at their cell surface, and this upregulation was dependent on effective ADCC. The same observation was made with trastuzumab and cetuximab in the presence of HER-positive and EGFR-positive tumors, respectively. Using an agonistic anti-CD137 antibody, we demonstrate that triggering CD137 on NK cells enhanced the antitumor activity of rituximab, trastuzumab and cetuximab in vitro and in vivo. I will present various additional means to enhance ADCC by blocking inhibitory signals, such as CD47 on macrophages, IL-15 on monocytes or DCs, KIR or PD-1 on NK cells.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 29 Jun 2026
Molecular Immunotherapy: Advancing Targeted Approaches for Immune-Based Disease Management
Short communication · 29 Dec 2025
Targeting Immune Pathways for Autoimmune Disease
Editorial · 29 Jul 2025
Immune Checkpoints: Targets, Resistance, and Future Therapies
Short communication · 30 Jun 2025
Dendritic Cells: Diverse Immunity, Therapeutic Targets.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Holbrook Kohrt”

